Key Points o + Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related obesity disorders, including Bardet-Biedl Syndrome (BBS) and hyperphagia, an extreme, uncontrollable and compulsive compulsion to eat. Rhythm is a Phase 3 clinical trial for hypothalamic disorder (HO), a type of obesity caused by a damaged h ...